Shots:

• The positive opinion is based on largest pre-registration clinical programme assessing Esperoct (FD- IV- q4days) in 270 patients previously treated with severe hemophilia A and more than 5 years of clinical exposure  
• The study resulted in effective routine prophylaxis in people with severe hemophilia A- efficacious in treatment and control of bleeding episodes and perioperative management- well tolerated and safe- maintained low median ABR of 1.18 when dosed at 50 IU/kg q4days
• Esperoct (turoctocog alfa pegol- N8-GP) is a replacement therapy with an extended half-life factor VIII molecule indicated for people with prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescents (>=12 years of age) and adults with hemophilia A   

Click here to read full press release/ article | Ref: Novo Nordisk | Image: Behance